In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naïve HIV-infected men who have sex with men

Arch Virol. 2020 Dec;165(12):2915-2919. doi: 10.1007/s00705-020-04823-z. Epub 2020 Sep 25.

Abstract

Human immunodeficiency virus type 1 (HIV) primary drug resistance mutations (DRMs) influence the long-term therapeutic effects of antiretroviral treatment (ART). Drug-resistance genotyping based on polymerase gene sequences obtained by next-generation sequencing (NGS) was performed using samples from 10 ART-naïve HIV-infected men who have sex with men (MSM; P1-P10) from the acute/early to chronic stage of infection. Three of the 10 subjects exhibited the presence of major (abundance, ≥ 20%) viral populations carrying DRM at early/acute stage that later, at the chronic stage, dropped drastically (V106M) or remained highly abundant (E138A). Four individuals exhibited additional DRMs (M46I/L; I47A; I54M, L100V) as HIV minority populations (abundance, 2-20%) that emerged during the chronic stage but ephemerally.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Drug Resistance, Viral / genetics*
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / genetics*
  • High-Throughput Nucleotide Sequencing
  • Homosexuality, Male
  • Humans
  • Male
  • Mutation*
  • Phylogeny
  • Sexual and Gender Minorities
  • Viral Load

Substances

  • Anti-HIV Agents